Shares of Lupin Ltd. 0.95 per cent to Rs 2168.10 at 12:32PM hours (IST) on Monday. Earlier in the day, the stock saw a gap up start to the session.

As per data available on BSE, total traded quantity on the counter stood at 8,294 shares with a turnover of Rs 1.79 crore till 12:32PM (IST). The stock traded at a price-to-earnings (P/E) multiple of 37.76, while the price-to-book value ratio stood at 5.16.

Return on equity (ROE) was at 13.5 per cent, according to exchange data. The stock hit an intraday high of Rs 2190.00 and a low of Rs 2128.85 during the session and quoted a 52-week high price of Rs 2312.00 and a 52-week low of Rs 1200.35.

The stock’s beta value, which measures its volatility in relation to the broader market, stood at 0.7458.

Technical Indicators

The 200-DMA (day moving average) of the stock stood at Rs 1891.73 on December 23, while the 50-DMA was at Rs 2119.93. If a stock trades above 50-DMA and 200-DMA, it usually means the immediate trend is upward. On the other hand, if the stock trades below 50-DMA and 200-DMA, it is considered a bearish trend. If it trades between 50-DMA and 200-DMA, then it suggests the stock can go either way. The Relative Strength Index (RSI) of the stood at 58.82. The RSI oscillates between zero and 100. Traditionally, a stock is considered overbought when the RSI value stands above 70 and oversold when it is below 30. Promoter holding

As of 30-Sep-2024, promoters held 46.96 per cent stake in the company, while FIIs held 21.5 per cent and domestic institutional investors had 25.06 per cent.

Shares of Lupin Ltd. gained 1.64 per cent to Rs 1815.85 in Monday’s trade as of 10:30AM (IST). The stock hit a high price of Rs 1817.2 and low of Rs 1767.2 during the session.

The return on equity (ROE) for the stock stood at 13.5 per cent. Traded volume on the counter stood at 10:30AM shares and turnover at Rs 0.54 crore around that time. The stock of Lupin Ltd. quoted a 52-week high price of Rs 1847.6 and 52-week low prices of Rs 931.4, respectively.

The stock’s Beta value, which measures its volatility in relation to the broader market, stood at 0.75.

Promotor/FII Holding

Promoters held 46.7 per cent stake in the company as of 30-Jun-2024, while overseas investors held 19.32 per cent and domestic institutional investors had 16.23 per cent.

Key Financials

The company reported consolidated sales of Rs 4990.04 crore for the quarter ended 31-Mar-2024, down 4.53 per cent from previous quarter’s Rs 5226.78 crore and down 11.7 per cent from the year-ago quarter’s Rs 4467.35 crore. Net profit after tax for the latest quarter stood at Rs 359.43 crore, up 52.33 per cent from the same quarter a year ago. Technicals
The MACD signalled a bullish bias on the counter. The MACD is known for signalling trend reversals in traded securities or indices.
It is the difference between the 26-day and 12-day exponential moving averages. A nine-day exponential moving average, called the signal line, is plotted on topof the MACD to reflect “buy” or “sell” opportunities. When the MACD crosses below the signal line, it gives a bearish signal, indicating that the price of the security may see a downward movement and vice versa.

Pharma company Lupin on Monday reported a 52% year-on-year (YoY) growth in its consolidated net profit at Rs 368 crore for the quarter ended March 2024. The same stood at Rs 242 crore in the last year quarter.

Revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.

The company’s Board has also declared a dividend of Rs 8 per share on the face value of Rs 2 each for the financial year ended March 2024.

EBITDA for the reporting quarter rose by a robust 67% YoY to Rs 1,026 crore. It was Rs 615 crore a year ago. EBITDA margins, meanwhile, expanded 680 basis points compared with the year-ago period to 21%.

“We continue to move forward with sustainable and profitable growth and delivered another strong set of numbers in Q4,” said Nilesh Gupta, MD, Lupin.US sales remained healthy during the quarter, driven by inhalation products, and the India formulation business is delivering ahead of the market.”While FY24 has been a year of resurgence for the company, we look forward to an even stronger FY25 driven by growth across our key geographies and consistent improvement in our margins,” Gupta further said.Region wise, North America sales were Rs 1901 crore, up 22% YoY and accounted for 39% of Lupin’s global sales. The US during the quarter was at $209 million, down from $212 million in the preceding quarter, but higher than $175 million in the previous year quarter.

The company filed 1 ANDA in the quarter, received 12 ANDA approvals from the US FDA, and launched 6 products in the quarter in the US Lupin now has 161 generic products in the US.

The company continues to be the third largest pharmaceutical player in both the US generic market and US total market by prescriptions.

Meanwhile, India formulation sales were up 8% YoY to Rs 1601 crore, accounting for 33% of Lupin’s global sales. Growth markets sales for the fourth quarter increased 16% YoY to Rs 509 crore.

The global API sales for the reporting quarter were down 20% YoY to Rs 258 crore.